199 related articles for article (PubMed ID: 32763659)
21. Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature.
Asonitis N; Angelousi A; Zafeiris C; Lambrou GI; Dontas I; Kassi E
Horm Metab Res; 2019 Dec; 51(12):770-778. PubMed ID: 31826272
[TBL] [Abstract][Full Text] [Related]
22. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
23. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
24. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
[TBL] [Abstract][Full Text] [Related]
25. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
26. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
27. [Hypercalcemia of malignancy: clinical features, diagnosis and treatment].
Farias ML
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):816-24. PubMed ID: 16444366
[TBL] [Abstract][Full Text] [Related]
28. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
29. Hypercalcemia and bone resorption in malignancy.
Walls J; Bundred N; Howell A
Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618
[TBL] [Abstract][Full Text] [Related]
30. Hypercalcemia and parathyroid disorders.
Endres DB
Curr Opin Rheumatol; 1992 Jun; 4(3):383-8. PubMed ID: 1599819
[TBL] [Abstract][Full Text] [Related]
31. [PTHrP and breast cancer].
Devys A; Lortholary A; Audran M
Bull Cancer; 2001 Nov; 88(11):1075-80. PubMed ID: 11741801
[TBL] [Abstract][Full Text] [Related]
32. [Biphosphonate therapy in the management of skeletal metastases].
Grauer A; Ziegler R
Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
34. Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift.
O'Callaghan S; Yau H
Endocr Connect; 2021 Jan; 10(1):R13-R24. PubMed ID: 33289687
[TBL] [Abstract][Full Text] [Related]
35. A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).
Shimizu H; Monden T; Tomotsune T; Nakatani Y; Domeki N; Matsumura M; Jojima T; Kawagoe Y; Kasai K
Intern Med; 2011; 50(24):2993-6. PubMed ID: 22185991
[TBL] [Abstract][Full Text] [Related]
36. Treatment of chronic hypercalcemia.
Camozzi V; Luisetto G; Basso SM; Cappelletti P; Tozzoli R; Lumachi F
Med Chem; 2012 Jul; 8(4):556-63. PubMed ID: 22571196
[TBL] [Abstract][Full Text] [Related]
37. Therapy of malignancy-associated hypercalcemia: 1983.
Stewart AF
Am J Med; 1983 Mar; 74(3):475-80. PubMed ID: 6219580
[TBL] [Abstract][Full Text] [Related]
38. Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
Colak U; Mutlu GY; Sozmen BO; Yucel EB; Kayserili H; Hatun S
J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1403-1406. PubMed ID: 31782950
[TBL] [Abstract][Full Text] [Related]
39. [Refractory hypercalcemia in patient with lung cancer].
Grzywacz A; Dziuk M; Niemczyk S
Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of malignancy-associated hypercalcemia].
Endo I; Inoue D
Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
